About Oruka Therapeutics, Inc.
http://www.orukatx.comOruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
CEO
Lawrence Otto Klein
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-09-03 | Reverse | 1:12 |
| 2019-04-04 | Reverse | 1:18 |
ETFs Holding This Stock
Summary
Showing Top 3 of 98
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
FMR LLC
Shares:7.26M
Value:$232.24M
VR ADVISER, LLC
Shares:4.15M
Value:$132.75M
FAIRMOUNT FUNDS MANAGEMENT LLC
Shares:3.71M
Value:$118.57M
Summary
Showing Top 3 of 108
About Oruka Therapeutics, Inc.
http://www.orukatx.comOruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $34.1M ▲ | $-30.28M ▼ | 0% | $-0.69 ▼ | $-30.26M ▼ |
| Q2-2025 | $0 | $28.43M ▲ | $-24.57M ▼ | 0% | $-0.58 ▼ | $-24.55M ▼ |
| Q1-2025 | $0 | $25.09M ▼ | $-21M ▲ | 0% | $-0.5 ▲ | $-20.98M ▲ |
| Q4-2024 | $0 | $38.33M ▲ | $-33.39M ▼ | 0% | $-1.54 ▲ | $-37.44M ▼ |
| Q3-2024 | $0 | $29.45M | $-28.62M | 0% | $-1.91 | $-28.12M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $349.15M ▲ | $509.25M ▲ | $22.46M ▲ | $486.79M ▲ |
| Q2-2025 | $328.41M ▼ | $357.42M ▼ | $13.78M ▲ | $343.64M ▼ |
| Q1-2025 | $349.09M ▼ | $377.11M ▼ | $12.39M ▼ | $364.73M ▼ |
| Q4-2024 | $375.65M ▼ | $396.02M ▼ | $13.8M ▼ | $382.22M ▲ |
| Q3-2024 | $410.88M | $414.09M | $71.72M | $342.37M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-30.28M ▼ | $-21.6M ▲ | $-122.45M ▼ | $169.91M ▲ | $25.86M ▲ | $-21.7M ▲ |
| Q2-2025 | $-24.57M ▼ | $-23.14M ▼ | $4.86M ▼ | $109K ▲ | $-18.18M ▼ | $-23.18M ▼ |
| Q1-2025 | $-21M ▲ | $-20.87M ▼ | $42.87M ▲ | $0 ▲ | $22M ▲ | $-20.88M ▼ |
| Q4-2024 | $-25.78M ▲ | $-18.82M ▲ | $-329.96M ▼ | $-526K ▼ | $-349.3M ▼ | $-18.84M ▲ |
| Q3-2024 | $-28.62M | $-34.86M | $-171K | $450.05M | $377.59M | $-35.03M |
CEO
Lawrence Otto Klein
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-09-03 | Reverse | 1:12 |
| 2019-04-04 | Reverse | 1:18 |
ETFs Holding This Stock
Summary
Showing Top 3 of 98
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
FMR LLC
Shares:7.26M
Value:$232.24M
VR ADVISER, LLC
Shares:4.15M
Value:$132.75M
FAIRMOUNT FUNDS MANAGEMENT LLC
Shares:3.71M
Value:$118.57M
Summary
Showing Top 3 of 108